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ABSTRACT
Introduction: Early biological treatment of rheumatoid arthritis (RA) may reverse the autoimmune response
in some patients resulting in favorable long-term outcomes. Although the cost-effectiveness of this strategy
has been questioned, biosimilar entries warrant the revision of clinical and pharmaco-economic evidence.
Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) published up
to 24 May 2018 in Pubmed, EMBASE and Cochrane CENTRAL, comparing infliximab with non-biological
therapy in patients with RA naïve to methotrexate. We performed meta-analyses for efficacy outcomes
at month 6 and years 1 and 2. Six RCTs were identified, involving 1832 patients. At month 6 ACR70
response and remission, and at year 1 ACR20/ACR70 responses and remission were improved signifi-
cantly with first-line infliximab versus control. The differences were not significant at year 2. We
reviewed cost-utility studies, up to 31 October 2018 in PubMed, Cochrane CENTRAL and the CRD
HTA databases. Four studies indicated that first-line use of originator infliximab calculated at 2005–2008
prices was not cost-effective.
Expert opinion: We demonstrated the efficacy benefits of first-line infliximab therapy up to 1 year in
methotrexate-naïve RA. We highlighted the need for standardized reporting of outcomes and conduct-
ing cost-effectiveness analyses of first-line biosimilar therapy in RA.
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1. Introduction
Rheumatoid arthritis (RA) affects the synovial joints, causing
inflammation and pain. Without treatment, progressive destruc-
tion of the joints can lead to considerable disability [1–3]. Patients
with early or ‘recent-onset’ RA can be defined as individuals with
a disease duration of 2 years or less [1,2]. Of late, there has been
increasing emphasis on the prompt referral of patients with
suspected early RA to rheumatologists in order to prevent irre-
versible joint damage [1,2]. Effective early treatment within the
therapeutic ‘window of opportunity’ for RA may reverse the
autoimmune response in some patients, leading to more favor-
able long-term outcomes compared with patients who are trea-
ted later in the disease course [4,5]. Moreover, achievement of
early response may allow eventual tapering of RA treatment and
potential drug-free remission in some patients [6].
Tumor necrosis factor inhibitors (TNFis) and other biological
disease-modifying antirheumatic drugs (bDMARDs) have tradition-
ally been used to treat patients with long-standing RA who have
experienced inadequate response to previous conventional syn-
thetic DMARDs (csDMARDs) such as methotrexate (MTX) or leflu-
nomide. However, a number of studies have demonstrated that
TNFi treatment is also effective in patients with early RA [7–15].
Indeed, several bDMARDs, including infliximab and other TNFis,
have now been approved for the first-line treatment of patients
with severe, active and progressive disease that has not been
treated with MTX or other csDMARDs [16]. Recent meta-analyses
have demonstrated the short-termbenefits of biologic agents over
csDMARDs in early, MTX/csDMARD-naïve RA, suggesting that
more patients may achieve remission with first-line biological
therapy than with csDMARDs [3,17–19]. However, the selection
of studies in these meta-analyses were diverse and sometimes
incomplete [3,17,18].
At the current time, bDMARDs such as infliximab are not
widely used in first-line treatment of patients with early RA
[16,20]. This fact is likely to be at least partly related to the
most recent (2016) guidance on this topic issued by the
European League Against Rheumatism (EULAR) [21] and
National Institute for Health and Care Excellence (NICE) [16],
both of which do not recommend first-line treatment with
bDMARDs in patients with RA. The EULAR recommendations
note that the early use, and potential for subsequent with-
drawal, of bDMARDs was discussed, but was not supported by
the majority of members of the recommendations task force
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[21]. One reason for this was the lack of evidence for super-
iority of bDMARDs compared with the combination of MTX
plus glucocorticoid. Furthermore, the task force commented
that in the context of a treat-to-target strategy, initial use of
csDMARDs has equivalent long-term efficacy. The cost-
effectiveness of first-line bDMARD therapy was also ques-
tioned and considered to be poor given the lack of evidence
supporting its superior long-term efficacy [21]. EULAR there-
fore recommend the use of MTX in combination with short-
term glucocorticoid as a first-line strategy for the treatment of
RA. Following treatment failure with initial csDMARD therapy,
additional csDMARDs or bDMARDs/targeted synthetic
DMARDs may be initiated, depending on the prognostic status
of each patient. The EULAR recommendations further state
that tapering of bDMARDs should be considered if the patient
is in sustained remission [21]. NICE recommend the use of
bDMARDs in combination with MTX for patients with severe
RA (disease activity score [DAS] 28 > 5.1) following csDMARD
therapy [16].
The lack of uptake of biologic agents for the first-line
treatment of RA may also be due to high drug costs [20].
However, the introduction of biosimilar versions of RA-
approved drugs may help to reduce treatment costs, with
the availability of biosimilar infliximab since 2013 already
leading to considerable price discounts in some regions
[22]. Budget impact analyses have predicted large health-
care savings following the uptake of biosimilar infliximab in
RA across multiple markets [23–25]. There is, however,
a need for more recent cost-effectiveness analyses that
take into account recent reductions in the cost of some
bDMARDs following the introduction of biosimilars.
Because of its comparable efficacy and lower cost versus
originator infliximab, biosimilar infliximab may be an ideal
candidate with which to reassess the available medical and
economic evidence for first-line biological therapy in MTX-
naïve, early RA. The aims of our study, therefore, were to
systematically review the literature and analyze the out-
comes of first-line infliximab treatment versus other
treatment strategies in patients with MTX-naïve RA, with
a special focus on long-term efficacy outcomes. We also
reviewed available health economic literature for infliximab
cost-utility studies in this patient population.
2. Methods
2.1. Search strategy for clinical studies
We conducted a systematic literature search in PubMed, EMBASE
and the Cochrane Central Register of Controlled Trials (CENTRAL)
up to 24 May 2018. Our search included the Cochrane filter for
clinical trials [26], all known development codes of infliximab
[27–29], and the MeSH term for RA. Full details of the PubMed,
Embase and CENTRAL search criteria are shown in
Supplementary Tables S1, S2 and S3, respectively. To identify
papers not yet indexed by MeSH terms, we conducted another
search in PubMed without including RA as a keyword for the
period of January 1 to 24 May 2018 (Supplementary Table S1).
2.2. Selection of clinical studies
Eligible studies included published randomized controlled trials
(RCTs) involving patients with RA who were MTX-naïve at rando-
mization. The treatment intervention of interest was infliximab.
Control treatments could include any pharmacological treatment
(i.e. placebo, csDMARDs and/or steroids) with or without conco-
mitant MTX that did not involve any biological therapy at study
initiation, although biological treatment could be included per
protocol in a later phase of the study. Multiple publications from
the same RCT were retained, including RCT extension studies. We
did not impose any language restrictions on our search, but we
excluded case studies, pooled analyses, review articles and con-
ference abstracts.
For mapping available evidence, outcomes of interest included
any physician- or patient-reported clinical efficacy, economic or
radiological outcome, as well as any key safety outcomes such as
occurrence of adverse events (AEs), discontinuations due to AEs,
deaths, infusion reactions, severe infections, tuberculosis, malig-
nancy, cardiovascular events and immunogenicity (i.e. the pre-
sence of anti-drug antibodies [ADAs]). For quantitative syntheses,
we included studies reporting American College of Rheumatology
(ACR) response criteria (ACR20/ACR70) or clinical remission (see
‘Data extraction’ section below for definitions) measured atmonth
6, year 1 and year 2. The abstract of each potential publication was
reviewed by two independent researchers to confirm relevance
and, if needed, a third independent researcher resolved any
differences.
2.3. Data extraction from clinical studies
All reported outcomes (detailed above) and corresponding
time points for all relevant primary and secondary publications
of the selected studies were recorded. For quantitative synth-
esis, a Microsoft Excel spreadsheet was developed to capture
the following details of relevant studies by treatment arm:
study name; reference; treatment and dosing; number of ran-
domized patients, risk of bias assessment; ACR20, ACR70 and
Article highlights
● We performed a systematic search of the literature for RCTs of infliximab
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between 1-10 years.
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therapy in early RA. The cost-effectiveness of this strategy at biosi-
milar prices is yet to be determined.
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remission based on any criteria (ACR, EULAR, DAS in 28 or 44
joints [DAS28/DAS44], Simple Disease Activity Index [SDAI] or
Clinical Disease Activity Index [CDAI]) at month 6, year 1
and year 2. If multiple remission measures were reported, we
used DAS28-erythrocyte sedimentation rate (ESR) if available,
or the measure with highest number of patients in remission
in the treatment arms combined.
2.4. Risk of bias assessment of clinical studies
The Cochrane Risk of Bias Tool [26] was applied to all studies. In
short, based on the overall assessment of available information on
randomization, treatment allocation concealment, blinding of par-
ticipants, personnel and outcome assessments, the attrition of
participants as well as the reporting of outcomes and other
potential sources, we categorized studies as having a low, high
or unknown risk of bias. Due to the transitions between double-
blind and open-label observation strategies at various time points,
risk of bias was assessed separately at month 6, year 1 and year 2.
2.5. Meta-analysis of clinical endpoints
All endpoints were included on an intent-to-treat basis, using the
number of patients initially randomized. Calculations were per-
formed using the Stata14 statistical software package (StataCorp
LLC., College Station, Texas, USA). Due to the heterogenous
design of studies, we chose different quantitative synthesis
methods for pre-defined short- and long-term outcomes. For
month 6 outcomes, a network meta-analysis using the Stata
network meta package was performed comparing the infliximab
plus MTX combination, multiple DMARD combinations with cor-
ticosteroid with or without infliximab, steroid and MTX combina-
tions, and MTX monotherapy, using MTX monotherapy as
control [30]. There was no source of loop-inconsistency (i.e.
incomparable results from direct and indirect comparisons)
within the network, therefore we applied the consistency net-
work meta-analysis model (assuming random effects for study
heterogeneity but no inconsistency between direct- and indirect
comparisons). Due to the changes in applied treatments and
observation strategies from month 6, treatment arms used in
the network meta-analysis were not feasible for later outcomes.
Rather, treatments were dichotomized according to a first-line
infliximab treatment versus other strategies (control) at rando-
mization, and, – considering the heterogeneity of studies – out-
comes at year 1 and 2 were assessed using a random effects
meta-analysis according to the method of DerSimonian and
Laird [31]. Month 18 outcomes were included in the meta-
analysis at year 2, if no year 2 outcomes were available from
the same study. For ACR20, ACR70 and remission, log odds ratios
(ORs) with 95% confidence intervals were applied for the com-
parisons. The significance threshold was set at p < 0.05.
We also investigated how the results of our analysis at year 2
would have changed if the ASPIRE trial [15], a 1-year parallel
design study of first-line infliximab versus placebo in combination
with MTX, had included a long-term extension study. We pro-
jected hypothetical year 2 ACR70 results in the ASPIRE study
using published year 1 ACR70 data and included the simulated
results in our meta-analysis.
2.6. Search for cost-utility studies
We also searched for cost-utility studies of first-line infliximab in
PubMed, Cochrane CENTRAL and the Centre for Reviews and
Dissemination (CRD) Health Technology Assessment (HTA) data-
base of the University of York up to 31 October 2018. The search-
terms included keywords for economic analyses, infliximab and
the MeSH terms for rheumatoid arthritis. Full details of the
PubMed, CENTRAL and CRD search criteria are shown in
Supplementary Tables S4, S5 and S6, respectively. Eligible studies
included those that reported incremental cost-effectiveness ratio
(ICER) values for infliximab in patients with MTX-naïve RA. Full text
manuscripts were considered. Data extraction for main character-
istics of the evaluations (publication year, country, type of model,
time horizon applied, data sources used, study sample, applied
treatments and comparators, year of costs, studyperspective, ICER)
was performed.
3. Results
3.1. Literature search of clinical studies
A PRISMA flow diagram for our systematic review is shown
in Figure 1 and includes the number of citations found and
screened. We identified six RCTs (reported in 26 full text
publications) of first-line infliximab in RA: ASPIRE (3 pub-
lications) [15,32,33], BeSt (15 publications) [34–48], Durez
2007 (1 publication) [49], IDEA (1 publication) [12], NEO-
RACo (3 publication) [50–52] and Quinn 2005 (3 publica-
tions) [53–55]. The sample size of these RCTs ranged from
20 to 1,049 patients; follow-up times were between 1 and
10 years. Key details of the studies are shown in Table 1.
Data from six studies (reported in eight publications
[12,15,34,35,38,49,51,53]) were included in the quantitative
synthesis. The studies included 1,832 patients at baseline,
of whom 1,009 (55%) received first-line infliximab.
Inclusion criteria for RA diagnosis was based on ACR cri-
teria in all six RCTs. Disease activity criteria was defined in
most studies as having ≥6 tender and swollen joints.
Disease duration was limited to between 3 months and
3 years.
Results were reported for 19 different time points and for
57 relevant endpoints, allowing 244 different time point–
outcome combinations (Supplementary Tables S7 and S8).
Of these, 188 (77%) were reported only by a single study, 39
(16%) by at least two studies and 17 (7%) by more than two
studies. Results of ACR response and remission rates by any
criteria were reported at month 6 by three [12,34,49] and
four [12,34,49,51] studies, respectively, and at year 1 by five
and four studies, respectively [12,15,34,49,51,53]. ACR20 and
ACR70 at year 1 were reported by four studies; all other
measures were reported by no more than three studies at
the same time point. Apart from three studies reporting
ACR70 outcomes at year 2 [35,51,53], longer-term results
(>1 year) for each measure were reported by a maximum
of two studies at the same time point (Supplementary
Tables S7 and S8). Although the presence of ADAs was
included among the pre-defined outcomes, none of the
studies reported ADA results.
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3.2. Methodological heterogeneity of clinical studies
The study designs showed great heterogeneity. The metho-
dological heterogeneity of studies and the treatment arms
are summarized in Figure 2 and Supplementary Table S9,
respectively. Patients were naïve to any DMARDs in three
studies [12,51,53], and were exposed to csDMARDs other
than MTX in two studies [34,49]. In ASPIRE [15], minimal
exposure to MTX was allowed. All patients were naïve to
bDMARDs. Two studies had a duration of 1 year [15,49] and
four studies had patient follow-up beyond 1 year
[12,34,51,53]. Randomized treatments changed substantially
between month 6 and year 2 in all studies. The BeSt [34]
study was an open-label, strategic, treat-to-target study
from the onset. In the NEO-RACo [51] and IDEA [12] studies,
patients continued an open-label, treat-to-target protocol
following 6 months of double-blind treatment. Patients in
the Quinn 2005 et al. [53] study could continue open-label
MTX treatment after cessation of infliximab at 1 year.
Infliximab was also discontinued in the NEO-RACo study
after 6 months [51].
3.3. Risk of bias analysis of clinical studies
At month 6 relevant outcomes were reported from four studies.
One study was a randomized, open-label, strategic trial and was
assessed as having a high risk of bias due to the lack of blinding
[34]. Three double-blind, randomized controlled studies had
a low risk of bias [12,49,51]. At year 1, three studies were cate-
gorized as high risk of bias due to their open-label design
[12,34,51], while outcomes were measured during the double-
blind randomized phase of three studies categorized as having
a low risk of bias [15,49,53]. At year 2, all studies were open-label
and were assessed as having a high risk of bias [12,34,51,53].
3.4. Meta-analyses of clinical studies
We performed network meta-analysis for efficacy outcomes at
month 6. The network map for 6-month ACR and remission
outcomes are displayed in Supplementary Figure S10. There
was no source of inconsistency in the network structure of the
included treatments, therefore we performed the network
meta-analysis using the consistency model assuming no
Figure 1. PRISMA flow diagram of the systematic review.
CENTRAL Cochrane Central Register of Controlled Trials; IFX infliximab, RA rheumatoid arthritis, RCT randomized controlled trial.
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treatment effect variation between designs [30]. ACR70 and
remission outcomes at 6 months were improved significantly
with first-line infliximab plus MTX compared with MTX control
(Table 2). ACR20 at 6 months was not significantly different
between the infliximab and control groups (Table 2).
At year 1 and year 2, first-line infliximab was compared with
other strategies via random effects meta-analysis. Heterogeneity
between studies was low and was not significant in the year 1
models. Our analyses showed that ACR20, ACR70 and remission
at year 1, significantly favored the infliximab group compared
with the control group (Table 2); ACR70 response at year 1 is also
shown in Figure 3(a). At year 2, there were no significant differ-
ences in outcomes (ACR20, ACR70 and remission) between the
infliximab and control groups (Table 2; Figure 3(b)).
Heterogeneity was significant in the year 2 ACR70 (I2 = 79.2%;
p = 0.002) and remission models (I2 = 75.8%; p = 0.006).
In studies with TNFis that had at least 1 year of a double-
blind, parallel phase and reported year 2 results (etanercept:
COMET [9], Ebrel ERA [56]; golimumab: GO-BEFORE [57,58];
adalimumab: PREMIER [8]; infliximab: Quinn 2005 [53]), there
was an additional 8.9% and 9.3% of patients with an ACR70
response at year 2 versus year 1 in the control group and TNFi
group, respectively. We assumed that ACR70 response rates of
the MTX alone and infliximab plus MTX combination arms in
ASPIRE would change from 21% and 38% in year 1 to 21% and
35.8% by year 2, respectively. Based on these results, projected
hypothetical year 2 ACR70 outcomes from the 1-year parallel
design ASPIRE study were included in our meta-analysis of
ACR70 response at year 2 (Figure 3(b)). Although
projected year 2 ACR70 data from ASPIRE increased the
between-group difference in favor of infliximab, the difference
remained non-significant (Figure 3(b)).
3.5. Summary of cost-effectiveness studies
Our searches yielded 96 abstracts in PubMed, 37 abstracts in
the Cochrane CENTRAL database and 123 abstracts in the CRD
HTA database. We removed 27 duplicates, 171 records based
on their title and two conference posters. From the remaining
56 records we identified four full text journal publications
reporting cost-utility studies of infliximab as first-line treat-
ment in patients with RA (Table 3). Two studies were con-
ducted in the United States, and the other studies were
conducted in the United Kingdom and the Netherlands.
ICERs ranged between €22,000/quality-adjusted life-year
(QALY) and £650,000/QALY (Table 3). The cost effectiveness
of first-line infliximab treatment was above the usually accep-
table financial threshold of the respective countries in most
models. All models were calculated with prices prior to the
registration of biosimilar infliximab by the European Medicines
Agency in 2013.
4. Conclusions
In summary, our systematic review and meta-analysis has
demonstrated that 1-year efficacy outcomes (ACR20, ACR70
and remission) were improved significantly with first-line
infliximab versus control strategies in patients with csDMARD-
naïve RA. These efficacy differences were not significant inTa
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a longer follow-up of 2 years. The diminished effect size and
precision of long-term estimates may partly be explained by
the highly diverse methodology of studies. The long-term
effects of first-line biological therapy on disease progression
should be further analyzed using all TNFi agents.
Analysis of cost-utility studies performed before the availability
of lower cost infliximab biosimilars revealed that first-line use of
originator infliximabwas not cost effective. New cost-effectiveness
analyses are needed in early RA that consider the sizable potential
savings resulting from the uptake of biosimilar infliximab.
Given the potentially considerable savings due to biosimilar
infliximab, the evident short-term efficacy benefits, the avail-
ability of prognostic factors for progressive disease and the
potential for biological-free remission if administered early,
the cost-effectiveness of first-line infliximab in early, treat-
ment-naïve RA should be re-assessed using biosimilar prices.
5. Expert opinion
The results of this systematic review and network meta-analysis
show that ACR70 and remission outcomes at 6 months in patients
with MTX-naïve RA were significantly improved with infliximab
versus MTX control. At year 1, ACR20, ACR70 and remission out-
comes were also significantly improved with infliximab versus
control strategies. However, at year 2, no statistically significant
differences inACR20, ACR70or remissionoutcomeswereobserved
between treatment groups. Long-term (>2 years) results on clinical
remission were available only from two RCTs (BeSt [34], NEO-RACo
[51]) and patient-reported outcome data were presented only
from the BeSt [34] and Quinn 2005 [53] studies.
We have demonstrated the need for improved standar-
dized reporting of studies. Despite the 244 reported time
point-outcome combinations, neither ACR response nor remis-
sion rates were reported by all studies at 6 months and 1 year,
and apart from ACR70, only two studies reported these effi-
cacy outcomes at the same time point after 1 year. For a given
time point only two outcomes were reported in four studies
and 13 outcomes were reported in three studies. The diverse
reporting of results is a major barrier for effective evidence
synthesis.
The included studies showed increasingly heterogenous
designs over time, which partly explains the smaller effect
sizes and increasing variance at year 2 compared with year 1
outcomes. However, due to the small number of studies, the
decomposition of study heterogeneity via meta-regression
was not feasible [26]. The randomized treatments were mod-
ified substantially beyond month 6 in all studies. In NEO-RACo
[51], infliximab treatment was discontinued after 6 months,
and in Quinn 2005 [53], after 12 months. In the BeSt study
[34,35] at year 2 nearly three quarters of initially randomized
patients received infliximab plus MTX combination therapy,
while in the DMARD monotherapy arm more than one quarter
of patients received infliximab. In IDEA [12] two thirds of
patients in the control arm received dose escalation, while
DMARDs were adjusted in more than half of the patients in
the infliximab arm, and infliximab was discontinued in every
fourth patient due to sustained low disease activity.
While five of the six studies measured endpoints in a double-
blind setting at month 6, year 2 efficacy outcomes were available
only from open-label studies. We hypothesize that longer-term
benefits of biologic combinations and MTX monotherapy would
be demonstrated in studies that remain blinded for longer peri-
ods. Therefore, using ACR70 data, we investigated how the
results of our analyses at year 2 might have changed if the
1-year longASPIRE study [15] had included a long-termextension
study. The absolute risk difference in ACR70 response at year 2
between the treatment and control arms in the PREMIER [8] and
COMET [9] studies were 26% and 25%, respectively. However, in
our analysis of hypothetical year 2 ASPIRE results, we assumed
a conservative 15% difference between infliximab plus MTX and
MTX monotherapy. Although the projected year 2 ACR70 data
from ASPIRE increased the between-group difference in favor of
infliximab, the difference remainednon-significant. Although loss
of sustained clinical response due to immunogenicity [63]may be
an alternative explanation for themoderate long-term effect size,
we found no reports of anti-drug-antibody levels in the included
studies (Supplementary Table S7).
Figure 2. Heterogeneity of studies.
IFX infliximab.
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A key strength of our study is that we provide
a comprehensive evaluation of efficacy endpoints that are
relevant for pharmacoeconomic analyses – ACR20, ACR70
and remission – at different time points from 6 months up
to long-term outcomes at 2 years. While the benefit of
immediate infliximab in preventing joint damage has been
shown over other treatment strategies [15,34], radiographic
progression was out of the scope of this review. Several other
recent meta-analyses have compared the combination of bio-
logic agents plus MTX over csDMARDs in early MTX-naïve RA
[3,17–19,64]. The Cochrane report from Singh et al. [3]
included analyses of ACR50, Health Assessment
Questionnaire (HAQ) scores and remission rates at <6 months,
6–12 month and >12 month time points. From the included
19 RCTs seven were infliximab studies; however, in one of
them all patients received MTX at baseline [3]. Cai et al. [17]
included 20 RCTs in the analysis of ACR20, ACR50 and ACR70
endpoints. In one of the five included infliximab studies, all
patients received three months of MTX induction therapy
before randomization [17]. Stevenson et al. [64] in
a comprehensive HTA report commissioned by NICE, synthe-
sized month 6 ACR and EULAR response outcomes for seven
biological drugs, including two infliximab trials. Albert et al.
[18] included one infliximab study in an indirect pairwise
meta-analysis of year 1 ACR20, ACR50 and ACR70 endpoints
from six RCTs of biologics + DMARD therapy. Donahue et al.
[19] reported less radiological progression and higher ACR50
response rates at year 1 with four TNFis in combination with
MTX versus MTX monotherapy. Three of the 13 trials included
infliximab. Taken together, data from these studies support
the results of our own analysis that, in the short-term, biolo-
gics combined with MTX are superior to MTX monotherapy in
terms of ACR and remission endpoints in early RA. To date, no
consistent evidence supports the superiority of one biologic
therapy over another.
In all the six RCTs, RA diagnosis was based on the 1987
ACR diagnostic criteria for RA [65], which have been criti-
cized for their lack of sensitivity in early disease [66]. The
new ACR/EULAR classification system introduced in 2010,
focuses on symptoms at earlier stages of the disease rather
than establishing the diagnosis by its late-stage features
[66]. Further studies using the new ACR/EULAR classification
system may contribute to a better understanding of the
effectiveness of first-line infliximab treatment in early-stage
RA. Moreover, we believe that there is a need for new
outcomes to detect the long-term effects of deteriorated
health patients may suffer due to the lack of early elimina-
tion of symptoms. These may include measures to assess
the impact on internalization and legitimization of societal
stereotypes of RA, subjective expectations regarding future
health and treatment goals, acceptability of symptoms,
uncertainty about the future, work capacity, long-term life
planning and wellbeing in terms of the ability to do things
that are important in patients’ lives [67–71].
In our cost-utility analysis, the cost-effectiveness of origi-
nator infliximab was deemed unacceptable in the published
economic analyses we reviewed, with ICERs of between
€22,000/QALY and £650,000/QALY reported. Due to the
broad variety of modelling assumptions of long-termTa
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outcomes, the results of cost-effectiveness analyses need to
be interpreted with caution. Although systematic reviews
did not demonstrate a substantial difference between
branded TNFi drugs in terms of efficacy, ICERs between
individual drugs differed considerably. In a review of six
cost-utility analyses by Stevenson et al. [64], ICERs were
>US$100,000/QALY in three of four infliximab studies, two
of five adalimumab studies, and five of six etanercept stu-
dies. Treating biological agents as a homogenous group,
Stevenson et al. estimated that the ICER for a first-line
biological strategy versus MTX monotherapy in MTX-naïve,
early RA was £58,300/QALY, still above the acceptable cost-
effectiveness threshold.
However, the available cost-effectiveness studies with
infliximab in MTX-naïve RA were performed before the mar-
ket entry of biosimilar competitors. The most recent
economic evaluation of MTX-naïve, early RA reported base
case results using 2013 innovator etanercept prices [72].
Reductions in the price of infliximab therapy due to the
entry of biosimilar products in the RA market could improve
the cost-effectiveness of first-line infliximab therapy for
patients with RA. The considerable cost saving achievable
with biosimilar infliximab along with the potential to
improve access to RA has been demonstrated in several
budget impact analyses [23–25,73]. We hypothesize that
given the considerable price reductions driven by biosimilar
competition, the cost-effectiveness of first-line infliximab
therapy may fall under the financing threshold in many
countries and allow use of this agent in the first-line setting
for the treatment of patients with early RA. If proven to be
cost effective, first-line therapy with biologic agents could
provide a valuable opportunity to test the window of
NOTE: Weights are from random effects analysis
Overall  (I−squared = 58.0%, p = 0.067)
Study
BeSt
Quinn 2005
ASPIRE
Durez
0.72 (0.60, 0.83)
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0.76 (0.67, 0.85)
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100.00
Weight
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Favours control Favours TNF−inhibitor 
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D+L Overall  (I−squared = 98.1%, p = 0.000)
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Figure 3. Random effects meta-analysis ACR70 response (a) at year 1 and (b) at year 2 with and without simulated ASPIRE results*.
*ASPIRE 2-year ACR70 response was projected from 1 year-long double-blind, parallel-group RCTsACR American College of Rheumatology, CI confidence interval, D + L DerSimonian & Laird
random effects meta-analysis, OR odds ratio, RCT randomized controlled trial
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opportunity hypothesis in a real-world setting and increase
the possibility for drug-free remission in some patients
with RA.
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